Prof Katja Weisel speaks to ecancer online at the EHA virtual conference about the GMMG-CONCEPT trial.
The GMMG-CONCEPT trial investigated the depth of response of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for front-line treatment of high-risk multiple myeloma.
Prof Weisel explains the results so far, and how this area of research is looking to improve over the next few years.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.